Gynecological surgery

Comagine Health Awarded Multiple New Maternal Health Contracts

Retrieved on: 
Thursday, November 2, 2023
HRSA, SMM, Public health, SPH, Mortality, Obstetrics, Workforce, Health, Population health, Health Resources and Services Administration, Pediatrics, Community, UNLV School of Medicine, University of Nevada, Las Vegas, UNLV, Partnership, University, Gynecological surgery, Safety, KSOM, Nursing, Management

SEATTLE, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Comagine Health, a leading national, nonprofit health care consulting firm, received multiple new maternal health contracts. The new work focuses on creating innovative approaches to address maternal health needs in Nevada and Oregon. The Health Resources and Services Administration (HRSA) awarded both contracts to Comagine Health as a part of its investment to address the maternal health crisis. The new contracts add to Comagine Health's growing portfolio of federal contracts.

Key Points: 
  • SEATTLE, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Comagine Health, a leading national, nonprofit health care consulting firm, received multiple new maternal health contracts.
  • The Health Resources and Services Administration (HRSA) awarded both contracts to Comagine Health as a part of its investment to address the maternal health crisis.
  • State Maternal Health Innovation Program: This program will reduce maternal mortality and severe maternal morbidity (SMM) by addressing maternal health disparities related to substance use disorder through the development of quality services, a skilled workforce, enhanced data quality and capacity, and innovative programming.
  • "The goal of this work aligns extraordinarily well with Comagine Health's mission of taking on tough problems in health care in order to improve population health."

Asensus Surgical to Participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Retrieved on: 
Monday, November 28, 2022
Deep learning, PARK, Emerging technologies, Gynaecology, Conference, Gynecological surgery, Health, AdventHealth, NYSE, Sale, Ophthalmology, Surgeon, Commercial, Intelligence, Da Vinci Surgical System, RESEARCH, Opinion, Pharmaceutical industry, Dentistry

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference in Miami, Florida.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference in Miami, Florida.
  • The Companys panel presentation, Launching on Society: Early Commercial MedTech Names with New Technologies in Large Patient Populations, will take place on Thursday, December 8, 2022 at 11:00 AM Eastern Time.
  • This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability.
  • Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com .

Hologic to Launch the NovaSure® V5 Global Endometrial Ablation Device at Upcoming American Association of Gynecologic Laparoscopists 50th Global Congress

Retrieved on: 
Tuesday, November 2, 2021
Medical Devices, Health, Consumer, Surgery, Women, Biotechnology, Woman, Infection, MD, Fractionation Research Inc., V5, Association, Faecal calprotectin, Â, Menstrual disorder, Partnership, IFU, Patient, FDA, ISBN, Cramp, Suction, Ablation, Nausea, Congress, Anatomy, Vomiting, Physician, Pregnancy, Perforation, Use, Multimedia, HOLX, Gold, Health, Nasdaq, Research, American Association, AAGL, Science, Gynecological surgery, GEA, Pharmaceutical industry, Medical imaging, Birth control

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure V5 global endometrial ablation (GEA) device at the American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress on (November 14-17).

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure V5 global endometrial ablation (GEA) device at the American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress on (November 14-17).
  • The most studied and trusted endometrial ablation procedure in the United States, the innovative new NovaSure V5 device represents Hologic's ongoing commitment to enhance the physician experience.1
    This press release features multimedia.
  • Guided by womens unique needs and the physicians that treat them, the NovaSure V5 device features several innovations, making it the most sophisticated device in the NovaSure family.
  • The NovaSure V5 device will be on display at the Hologic booth #536 and online at Hologics virtual surgery suite ( https://hologic.protoexpo.com/surgical/ ).

Global Electrosurgery Market to Reach $5.2 Billion by 2024

Retrieved on: 
Wednesday, August 11, 2021
Smoke, Intelligence, Gastroenterology, Internet, Incidence, Gynecological surgery, Patient, Cardiac arrest, General surgery, Forecasting, CAGR, Risk, Immune system, Geography, Cancer, ATMOS, Olympus Corporation, Coagulation, Orthopedic surgery, GIA, COVID-19, Conditional sentence, Research, Electrosurgery, LLC, Prevalence, Generator, The Journal of Thoracic and Cardiovascular Surgery, Instrument, US, Ageing, Awareness, Degenerative disease, Boston Scientific, Gynaecology, Infection, Population, SAN, Players, Urology, Marketing, Medtronic, Neurology, Dentistry, Pharmaceutical industry

SAN FRANCISCO, Aug. 11, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Electrosurgery - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Aug. 11, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Electrosurgery - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Electrosurgery is projected to reach US$5.2 Billion by 2024, registering a compounded annual growth rate (CAGR) of 3.8% over the analysis period.
  • The market, estimated at US$1.6 Billion in 2019 is projected to reach US$2 Billion by the close of the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Superior Robotic Surgery Profitability vs. Laparoscopy Reported in New CAVA Robotics' Journal Publication

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Clinical medicine, Medical specialties, Surgical oncology, Gynaecology, Gynecological surgery, Hysterectomy, Reproductive system, Sterilization, Robot-assisted surgery, Laparoscopy, Michael Stifelman

Published in the June issue of the Journal of Robotic Surgery, the paper provides peer-review confirmation that best practice, higher-volume robotic surgeons generate high profitability in benign robotic hysterectomy cases vs. identical laparoscopic cases.

Key Points: 
  • Published in the June issue of the Journal of Robotic Surgery, the paper provides peer-review confirmation that best practice, higher-volume robotic surgeons generate high profitability in benign robotic hysterectomy cases vs. identical laparoscopic cases.
  • CAVA Robotics International was engaged by Catholic Health to incorporate 21 dimensions of robotic program best practices into their robotic program.
  • "Despite the rapid incorporation of robotic hysterectomy into clinical practice, prospective head-to-head evidence comparing robotic hysterectomy to traditional laparoscopy has been sparse," said Dr. Herb Coussons, CAVA's medical director.
  • "It is indeed possible for robotic surgery to equal, and even exceed, laparoscopy in a good number of case types, such as benign hysterectomy."

Free From Fibroids Will Raise Awareness of all Available Treatment Options for Symptomatic Uterine Fibroids

Retrieved on: 
Wednesday, June 30, 2021
Gynaecological neoplasia, Uterine fibroid, Clinical medicine, Medicine, Health, Gynecological surgery, Surgical instruments, Uterine myomectomy, Uterine artery embolization

WASHINGTON , June 30, 2021 /PRNewswire-PRWeb/ -- Today, Free From Fibroids and the Fibroid Coalition officially launched their efforts to raise awareness of all available treatment options for uterine fibroids.

Key Points: 
  • WASHINGTON , June 30, 2021 /PRNewswire-PRWeb/ -- Today, Free From Fibroids and the Fibroid Coalition officially launched their efforts to raise awareness of all available treatment options for uterine fibroids.
  • They have assembled a group of individuals who are passionate about providing patients and physicians with non-surgical treatment options for fibroids.
  • Uterine fibroids are diagnosed roughly three times more frequently in Black women and women of color than in white women of the same age.
  • Free From Fibroids is dedicated to the following:
    To support and empower women suffering with uterine fibroids.

Worldwide Myomectomy Industry to 2026 - Rise in Minimally Invasive Procedures is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Surgery, Health, Gynecological surgery, Clinical medicine, Medicine, Gynaecological neoplasia, Uterine fibroid, Uterine myomectomy, Medical specialties, Surgical instruments, Morcellator, Victor Bonney

According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.

Key Points: 
  • According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.
  • These guidelines resulted in surgeons delaying myomectomy procedures which will impact devices used in the myomectomy market.
  • With the rise in patients with uterine fibroids, the demand for myomectomy procedures will also increase.
  • These factors along with high reimbursement rates and government initiatives contribute to North America occupying the largest share within the Myomectomy market.

E. Stanton Shoemaker, MD, FACOG, is recognized by Continental Who's Who

Retrieved on: 
Friday, June 11, 2021
Medical specialties, Clinical medicine, Medicine, Incontinence, Urinary incontinence, Gynaecology, Urinary system, Menopause, Fecal incontinence, Gynecological surgery

Offering personalized, patient-centered obstetrician and gynecology services, Dr. Shoemaker's private practice is located at 5920 Saratoga Blvd #101.

Key Points: 
  • Offering personalized, patient-centered obstetrician and gynecology services, Dr. Shoemaker's private practice is located at 5920 Saratoga Blvd #101.
  • The office renders a full spectrum of services, including menopause treatments; body contouring, weight loss programs, urinary incontinence treatments, and hormone optimization.
  • Dr. Shoemaker's areas of expertise include high-risk pregnancy, pelvic floor reconstruction, hormone replacement therapy, and gynecological surgery.
  • Descending from a family history of medical professionals, Dr. Shoemaker's decision to enter the field was inherent.

Gynesonics Announces Positive Payer Coverage Issued by Blue Cross Blue Shield of Florida (Florida Blue) for the Sonata Treatment

Retrieved on: 
Thursday, June 10, 2021
Insurance, Surgery, Medical devices, Women, Professional services, Radiology, Health, Consumer, General Health, Medicine, Clinical medicine, Medical specialties, Gynecological surgery, Surgical oncology, Gynaecology, Uterine myomectomy, Hysterectomy, Uterus, Minimally invasive procedure, Fibroid, Uterine fibroid, Sonata System, Gynesonics, SONATA SYSTEM, GYNESONICS

The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations.

Key Points: 
  • The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations.
  • Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved.
  • This is a great decision by Florida Blue that recognizes the importance of offering this minimally invasive option to women.
  • They are recognizing the clinical efficacy of the Sonata Procedure and as a result are creating access to a less invasive treatment option with the Sonata System.

Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System

Retrieved on: 
Thursday, June 3, 2021
Professional services, Health, Medical devices, Surgery, Insurance, Managed care, General Health, Medicine, Clinical medicine, Medical specialties, Gynaecological neoplasia, Uterine fibroid, Surgical oncology, Interventional radiology, Gynecological surgery, Transcervical, Radiofrequency ablation, Uterus, Ablation, Sonata System, Gynesonics, SONATA SYSTEM, GYNESONICS

The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.

Key Points: 
  • The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.
  • Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.
  • This policy opens the way for their members to have the Sonata Procedure, the least invasive radio frequency ablation treatment for uterine fibroids, said Chris Owens, President and CEO of Gynesonics.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.